<DOC>
	<DOC>NCT01987167</DOC>
	<brief_summary>The goal of the study is to determine the earliest structural changes in the optic nerve during the acute event and during the twelve months of recovery following Acthar treatment.</brief_summary>
	<brief_title>Defining the Functional and Neuro-Protective Potential of ACTHAR in Acute Optic Neuritis</brief_title>
	<detailed_description>Determine the earliest structural changes in the optic nerve during the acute event and during the twelve months of recovery following Acthar treatment.</detailed_description>
	<mesh_term>Optic Neuritis</mesh_term>
	<mesh_term>Neuritis</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<criteria>unilateral acute demyelinating optic neuritis Able to provide informed consent age 18 or older can perform the above listed electrophysiologic diagnostic testing can perform high and low contrast visual acuity and visual field perimetry prior diagnosis of remitting/relapsing multiple sclerosis(RRMS) secondary progressive MS(SPMS) primary progressive MS (PPMS) undergoing treatment with medications approve for treatment of RRMS(except corticosteroids for a condition not involving central nervous system demyelination) prior diagnosis of systemic lupus erythematosis mixed connective tissue disease vasculitis sarcoidosis neuromyelitis optica</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>acute optic neuritis</keyword>
</DOC>